Table 2

Treatment and response overview

Treatment overviewAllNon-disease controlDisease controlP value
TIL succes rates, n
 TIL products/tumor resections30/34
 TIL products/enrolled patients30/31
 TIL-treated patients25178
TIL production, median (min–max)
 Young TIL expansion (days)23 (15–44)26 (18–44)20 (15–28)n.s.
 Resection to TIL infusion (days)44 (34–197)49 (34–197)43 (36–62)n.s.
 Cells in infusion product (10e9)61.2 (5–126)57 (5–126)67 (53–109)n.s.
 REP fold exp.2840 (265–6300)2605 (265–6300)3340 (2660–4748)n.s.
TIL product (REP TILs), median (min–max)
 CD3+ of live cells (%)97.4 (91.1–98.8)97.3 (91.1-98-8)97.5 (94.2–98.8)n.s.
 CD4+ of CD3+ (%)56.5 (2.2–95.4)56.5 (2.2–95.4)55.6 (4.7–87.0)n.s.
 CD8+ of CD3+ (%)31.9 (1.5–79.3)31.9 (1.5–71.7)37.2 (7.2–79.3)n.s.
Performance status at day −8
IL-2 doses, n
Nivolumab doses, n
Objective response
  • Summary of the TIL expansions and 25 treated patients. Patients were divided in disease control (PR or stable disease >4.5 months) and non-disease control groups depending on their objective response and its duration. Objective responses were assessed according to RECIST V.1.1.

  • n.s., not significant; PR, partial response; REP, rapid expansion protocol; SD, stable disease; TIL, tumor-infiltrating lymphocyte.